Interim report January-March 2018
Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the first quarter 2018.
IMPORTANT EVENTS DURING THE FIRST QUARTER
- In February, Vicore Pharma Holding acquired additional shares from an existing shareholder in I-Tech. As such, our holding amounted to 26.5%. In March, I-Tech issued shares to a new shareholder, Cambrex Karlskoga AB. Vicore Pharma Holding’s holding is consequently 21.2%.
IMPORTANT EVENTS AFTER THE PERIOD
- In April Vicore Pharma holds approval from the UK authorities and the Ethics Committee to initiate a Phase IIa Study on Idiopathic Pulmonary Fibrosis (IPF)
FINANCIAL SUMMARY (GROUP)
| KSEK | Jan-Mar 2018 | Jan-Mar 2017 | Year 2017 |
Year 2016 |
| Operating profit/loss | -4 235 | -2 456 | -12 793 | -6 649 |
| Profit/loss after financial items | 4 257 | -2 514 | -12 855 | -6 652 |
| Earnings per share, SEK | 0,27 | -0,16 | -0,81 | -0,54 |
| Equity as per end of period | 117 226 | 101 928 | 112 969 | 75 597 |
| Cash flow from operating activities | -2 261 | -2 474 | -7 703 | -7 289 |
| Cash flow from investing activities | -7 649 | -3 613 | -22 780 | -13 940 |
| Cash and cash equivalents as of end of period | 13 744 | 27 024 | 24 019 | 4 266 |
For more information, please contact:
Hans Jeppsson, CFO
M: +46 (0)70 553 14 65
hans.jeppsson@vicorepharma.com
This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 09.00 CET on May 8, 2018
About Vicore Pharma Holding
Vicore Pharma AB develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and USA. In addition, C21 is explored pre-clinically for a number of diseases where the AT2 receptor plays an important role. I-Tech AB is an associated company to Vicore Pharma Holding. The company has developed and commercialized Selektope® , an effective chemical agent used as an antifouling ingredient in antifouling paints. The companies are based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, please refer to www.vicorepharma.com
Tags: